Endocyte (ECYT) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Endocyte Reports Second Quarter 2016 Financial Results
August 4, 2016 4:01 PM EDTÂ Reached Maximum Tolerated Dose in Twice Weekly Dosing Schedule with EC1456
 Initiating EC1456 Expansion Cohort in Targeted Population of Folate Receptor-Positive Non-Small Cell Lung Cancer Patients
 Data Presentations Expected for EC1456 and EC1169 in the Second Half of 2016
 Conference Call Today at 4:30 p.m. EDTÂ
WEST LAFAYETTE, Ind., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT), a leader in developing targeted small molecule drug... More
